SCHEMBL15548916

SCHEMBL15548916

Cn1cc(Br)c2cc(Cl)ncc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 2/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34
GABRG3 Q99928 1/20 0.34
GABRQ Q9UN88 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
GSK3B P49841 2/20 0.32
AURKA O14965 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21370615 0.79 PIK3CB (0.46) MAP3K5GSK3BAURKAJAK2ABL1
SCHEMBL20225789 0.78 MAP3K5 (0.39) MAP3K5GABRPGABRDGABRA1GABRB1
SCHEMBL22291508 0.78 CSNK2A1 (0.38) MAP3K5CSNK2A1EGFR
SCHEMBL22291352 0.78 CSNK2A1 (0.35) MAP3K5CSNK2A1EGFR
Hydrochloric Acid SCHEMBL21329627 0.77 PIK3CB (0.45) MAP3K5GSK3BAURKAJAK2ABL1
SCHEMBL30633562 0.73 CHRNB2 (0.38) MAP3K5GABRPGABRDGABRA1GABRB1
SCHEMBL28756691 0.73 MAP3K5 (0.40) MAP3K5GABRPGABRDGABRA1GABRB1
SCHEMBL30511733 0.71 MAP3K5 (0.49) MAP3K5
SCHEMBL31581417 0.71 CHRM4 (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17282296 0.71 NFATC1 (0.44) GSK3BLRRK2NFATC1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106633-A1 TYK2 INHIBITORS BIOGEN MA INC. (US) 2025-05-22 WO disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MERCK SHARPE & DOHME CORP. 2015-11-26 US disclosed
EP-2855477-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS Merck Sharp & Dohme Corp. (US) 2015-04-08 EP disclosed
WO-2013181075-A1 ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336948-A1 Isotopically Labeled Biaryl Urea Compounds MAPT, SLC14A1, UBTF MAP3K5 3862/4885GABRP 835/4885GABRD 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.